{
  "metadata": {
    "description": "Vendor-published Medicare coverage information for OpenOnco tests",
    "lastUpdated": "2026-01-12",
    "sources": "Vendor websites, press releases, billing pages"
  },
  "vendors": {
    "Natera": {
      "billingPage": "https://www.natera.com/oncology/billing/",
      "tests": {
        "Signatera": {
          "lcd": "L38779",
          "lcdName": "MolDX: Molecular Residual Disease Testing for Cancer",
          "coveredIndications": [
            "Stage II-IV colorectal cancer",
            "Stage II-IV breast cancer",
            "Stage II-IV bladder cancer",
            "Stage II-IV ovarian cancer",
            "Stage I-IV NSCLC",
            "Pan-cancer immunotherapy monitoring"
          ],
          "reimbursement": null,
          "pressReleases": [
            { "date": "2025-06", "title": "Signatera Genome LCD coverage" },
            { "date": "2023-05", "title": "Pan-cancer immunotherapy coverage" }
          ]
        },
        "Signatera Genome": {
          "lcd": "L38779",
          "lcdName": "MolDX: Molecular Residual Disease Testing for Cancer",
          "coveredIndications": ["Same as Signatera"],
          "reimbursement": null
        },
        "Foresight CLARITY Lymphoma": {
          "lcd": null,
          "lcdName": null,
          "coveredIndications": [],
          "reimbursement": null,
          "notes": "Need to verify coverage status"
        }
      }
    },
    "Guardant Health": {
      "billingPage": "https://guardanthealth.com/billing-support/",
      "tests": {
        "Guardant360 CDx": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "article": "A56148",
          "coveredIndications": [
            "Recurrent, relapsed, refractory, metastatic, or advanced non-CNS solid tumors",
            "When tissue insufficient or unavailable"
          ],
          "reimbursement": null
        },
        "Guardant360 Liquid": {
          "ncd": "90.2",
          "coveredIndications": ["Same as Guardant360 CDx"],
          "reimbursement": null
        },
        "Guardant360 Response": {
          "lcd": "Treatment Response Monitoring",
          "coveredIndications": [
            "Metastatic/inoperable solid tumors on immune checkpoint inhibitors",
            "Baseline test + follow-up 4-10 weeks post-therapy"
          ],
          "reimbursement": "$3,500"
        },
        "Reveal MRD": {
          "lcd": "L38779",
          "coveredIndications": [
            "Stage II-III colorectal cancer",
            "Within 3 months post-curative intent therapy"
          ],
          "reimbursement": null
        },
        "Shield": {
          "ncd": "210.3",
          "ncdName": "Colorectal Cancer Screening Tests",
          "ncdSection": "B.3 Blood-based Biomarker Tests",
          "coveredIndications": [
            "Age 45-85",
            "Average risk, asymptomatic",
            "Once every 3 years"
          ],
          "reimbursement": "$1,495",
          "notes": "First FDA-approved blood test for CRC screening. ADLT status April 2025."
        },
        "Shield MCD": {
          "lcd": null,
          "coveredIndications": [],
          "notes": "Multi-cancer detection - coverage TBD pending FDA approval"
        }
      }
    },
    "Foundation Medicine": {
      "billingPage": "https://www.foundationmedicine.com/resource/billing-and-financial-assistance",
      "tests": {
        "FoundationOne CDx": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "ncdSection": "Section B (FDA CDx)",
          "coveredIndications": [
            "All solid tumors",
            "Treatment selection",
            "Clinical trial matching"
          ],
          "reimbursement": "97% of Medicare patients have $0 financial responsibility",
          "notes": "First FDA-approved CGP meeting NCD 90.2 requirements"
        },
        "FoundationOne Liquid CDx": {
          "ncd": "90.2",
          "ncdName": "Next Generation Sequencing (NGS)",
          "coveredIndications": [
            "Advanced solid tumors when tissue insufficient"
          ],
          "reimbursement": null
        },
        "FoundationOne Heme": {
          "ncd": "90.2",
          "coveredIndications": [
            "Hematologic malignancies",
            "Sarcomas"
          ],
          "reimbursement": null
        },
        "FoundationOne Tracker (MRD)": {
          "lcd": "L38779",
          "coveredIndications": [],
          "notes": "Partnership with Natera - uses Signatera platform"
        }
      }
    },
    "GRAIL": {
      "billingPage": "https://grail.com/galleri-test/",
      "tests": {
        "Galleri": {
          "ncd": null,
          "lcd": null,
          "coveredIndications": [],
          "reimbursement": "$949 (self-pay)",
          "notes": "NOT covered by Medicare. REACH study (IDE) provides coverage for 50,000 study participants only. Pending FDA approval and congressional action (H.R. 2407, S. 2085)."
        }
      }
    },
    "Exact Sciences": {
      "billingPage": "https://www.exactsciences.com/",
      "tests": {
        "Cologuard Plus": {
          "ncd": null,
          "lcd": null,
          "coveredIndications": [],
          "notes": "Need to verify coverage - different from original Cologuard"
        },
        "Oncoguard Liver": {
          "lcd": null,
          "coveredIndications": [],
          "notes": "Need to verify coverage status"
        },
        "Cancerguard": {
          "lcd": null,
          "coveredIndications": [],
          "notes": "MCED - likely no current coverage"
        },
        "Oncodetect": {
          "lcd": "L38779",
          "coveredIndications": [],
          "notes": "MRD test - likely covered under L38779"
        },
        "OncoExTra": {
          "ncd": "90.2",
          "coveredIndications": [],
          "notes": "CGP test - likely covered under NCD 90.2"
        },
        "Oncotype DX Breast Recurrence Score": {
          "lcd": null,
          "coveredIndications": ["HR+, HER2-, node-negative early breast cancer"],
          "reimbursement": "Covered",
          "notes": "Well-established test with broad coverage"
        }
      }
    }
  },
  "coveragePolicies": {
    "L38779": {
      "name": "MolDX: Molecular Residual Disease Testing for Cancer",
      "type": "LCD",
      "category": "MRD",
      "mac": "Multiple (Palmetto GBA administered)",
      "generalCriteria": [
        "Stage II-IV solid tumors",
        "Post-curative intent therapy",
        "Serial monitoring for recurrence"
      ]
    },
    "NCD90.2": {
      "documentId": 372,
      "name": "Next Generation Sequencing (NGS)",
      "type": "NCD",
      "category": "CGP/TDS",
      "sections": {
        "B": "FDA-approved companion diagnostics - nationally covered",
        "D": "Laboratory developed tests - MAC discretion"
      }
    },
    "NCD210.3": {
      "name": "Colorectal Cancer Screening Tests",
      "type": "NCD",
      "category": "ECD",
      "sections": {
        "B.3": "Blood-based Biomarker Tests"
      },
      "criteria": [
        "FDA market authorization required",
        "Sensitivity ≥74%",
        "Specificity ≥90%",
        "Age 45-85, average risk"
      ]
    },
    "L38043": {
      "name": "MolDX: Plasma-Based Genomic Profiling",
      "type": "LCD",
      "category": "CGP liquid biopsy"
    }
  },
  "vendorsToResearch": [
    "Tempus AI",
    "Caris Life Sciences",
    "NeoGenomics",
    "Personalis",
    "Labcorp",
    "Quest Diagnostics",
    "Adaptive Biotechnologies",
    "BillionToOne",
    "Memorial Sloan Kettering",
    "Strata Oncology"
  ]
}
